AR091490A1 - Antagonistas de iap - Google Patents
Antagonistas de iapInfo
- Publication number
- AR091490A1 AR091490A1 ARP130102157A AR091490A1 AR 091490 A1 AR091490 A1 AR 091490A1 AR P130102157 A ARP130102157 A AR P130102157A AR 091490 A1 AR091490 A1 AR 091490A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- compounds
- substituted alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos que modulan la actividad de los inhibidores de la actividad de la apoptosis (IAP), composiciones farmacéuticas que contienen esos compuestos y métodos para tratar trastornos proliferativos y trastornos de apoptosis desregulada, tal como cáncer, mediante el uso de los compuestos de la presente. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) en donde X es un enlace directo, -NH-, -O-, -NHCO- o -CONH-; R¹ es alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido o arilo opcionalmente sustituido; R² es alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, tioalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, arilalquilo opcionalmente sustituido o arilo opcionalmente sustituido; R³ y R⁴ son independientemente alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, arilalquilo opcionalmente sustituido, heteroarilalquilo opcionalmente sustituido o heterocicloalquilo opcionalmente sustituido; R⁵ y R⁶ son independientemente hidrógeno, alquilo opcionalmente sustituido o cicloalquilo opcionalmente sustituido; R⁷ y R⁸ son independientemente hidrógeno o alquilo opcionalmente sustituido; o una sal, un tautómero o un estereoisómero de aquel aceptables desde el punto de vista farmacéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661460P | 2012-06-19 | 2012-06-19 | |
US201361787808P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091490A1 true AR091490A1 (es) | 2015-02-11 |
Family
ID=48699353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102157 AR091490A1 (es) | 2012-06-19 | 2013-06-18 | Antagonistas de iap |
Country Status (6)
Country | Link |
---|---|
US (1) | US8889712B2 (es) |
EP (1) | EP2861581B9 (es) |
AR (1) | AR091490A1 (es) |
TW (1) | TW201402613A (es) |
UY (1) | UY34863A (es) |
WO (1) | WO2013192286A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2897949B1 (en) * | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
WO2015006524A1 (en) * | 2013-07-12 | 2015-01-15 | Bristol-Myers Squibb Company | Iap antagonists |
WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
JP6953435B2 (ja) * | 2016-05-09 | 2021-10-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二量体化合物 |
EA038128B1 (ru) | 2016-09-15 | 2021-07-09 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 |
CN110944719A (zh) * | 2017-07-25 | 2020-03-31 | 合帕吉恩治疗公司 | 凋亡蛋白的二聚肽抑制剂 |
AU2019309942A1 (en) * | 2018-07-23 | 2021-02-18 | Ohio State Innovation Foundation | Derivatives of papaverine that are effective hypoxic tumor radiosensitizers |
US11807641B2 (en) * | 2019-12-04 | 2023-11-07 | Omeros Corporation | MASP-2 inhibitors and methods of use |
WO2021113690A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
JP2023504541A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Masp-2阻害剤および使用方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212157A (en) | 1989-06-06 | 1993-05-18 | Bio-Mega, Inc. | Enzyme inhibitors |
WO2009136290A1 (en) | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
WO2013071027A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
WO2013071039A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
US20140309265A1 (en) | 2011-11-09 | 2014-10-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
-
2013
- 2013-06-18 UY UY0001034863A patent/UY34863A/es unknown
- 2013-06-18 TW TW102121605A patent/TW201402613A/zh unknown
- 2013-06-18 AR ARP130102157 patent/AR091490A1/es unknown
- 2013-06-19 WO PCT/US2013/046514 patent/WO2013192286A1/en active Application Filing
- 2013-06-19 EP EP13731637.8A patent/EP2861581B9/en not_active Not-in-force
- 2013-06-19 US US13/921,467 patent/US8889712B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2013192286A1 (en) | 2013-12-27 |
US8889712B2 (en) | 2014-11-18 |
EP2861581B9 (en) | 2017-08-30 |
UY34863A (es) | 2013-12-31 |
EP2861581B1 (en) | 2017-02-01 |
TW201402613A (zh) | 2014-01-16 |
US20130338081A1 (en) | 2013-12-19 |
EP2861581A1 (en) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091490A1 (es) | Antagonistas de iap | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
AR113299A1 (es) | Compuestos de isoindolina | |
CO2020000194A2 (es) | Inhibidores de quinasa alk2 que contienen imidazol | |
AR095347A1 (es) | Compuestos orgánicos | |
MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
AR093937A1 (es) | Compuestos quimicos | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
AR088246A1 (es) | Derivados de etinilo | |
CL2019000662A1 (es) | Inhibidores de dopamina–b–hidroxilasa. | |
BR112014030720A2 (pt) | inibidores de fbxo3 | |
PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |